Get the Stockscreener App
1.24
2.48%
0.03
Pliant Therapeutics Inc stock is traded at $1.24, with a volume of 266.47K.
It is up +2.48% in the last 24 hours and down -21.02% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
266.47K
Relative Volume:
0.24
Market Cap:
$76.20M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4013
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+1.64%
1M Performance:
-21.02%
6M Performance:
-4.62%
1Y Performance:
-90.81%
1-Day Range:
$1.19
$1.25
1-Week Range:
$1.19
$1.27
52-Week Range:
$1.1001
$14.26
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.24 | 74.35M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.60 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.41 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Can Pliant Therapeutics Inc. stock double in next 5 yearsTrade Volume Summary & Long-Term Safe Investment Ideas - DonanımHaber
Pliant Therapeutics appoints Minnie Kuo as COO - MSN
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transition2025 Buyback Activity & Verified Chart Pattern Signals - Улправда
BLRX Stock Analysis and ForecastVWAP Trading Strategies & Free Exceptional ROI Methods - earlytimes.in
What analysts say about Pliant Therapeutics Inc stockStock Screening Results & Free Explosive Wealth Accumulation - earlytimes.in
Pliant Therapeutics appoints Minnie Kuo as chief operating officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics appoints Minnie Kuo as chief operating officer - Investing.com
Pliant Therapeutics Appoints Minnie Kuo as COO - TipRanks
Pliant Therapeutics Appoints New Chief Operating Officer - TradingView — Track All Markets
Pliant Therapeutics (NASDAQ: PLRX) names Minnie Kuo Chief Operating Officer - Stock Titan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics, Inc. (PLRX) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre - Investing.com Nigeria
Pliant Therapeutics Announces Departure of Chief Medical Officer - TradingView
Pliant Therapeutics Inc (PLRX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre By Investing.com - Investing.com South Africa
Pliant Therapeutics shares rise after early cancer drug data impresses - MSN
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga
Pliant Therapeutics reports interim PLN-101095 Phase I trial data - Yahoo
Pliant’s PLN-101095 shows promising results in cancer trial By Investing.com - Investing.com Nigeria
Can Pliant Therapeutics Inc. stock sustain revenue growthJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - Newser
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), uniQure (QURE) and Medtronic (MDT) - The Globe and Mail
What hedge fund moves indicate for Pliant Therapeutics Inc. (9PT) stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - Newser
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerBear Alert & Risk Controlled Daily Plans - Newser
Why Is Pliant Therapeutics Stock Trading Lower TodayPliant Therapeutics (NASDAQ:PLRX) - Benzinga
Pliant Therapeutics, Inc. (PLRX) -15.3% in Intraday Trading: Interim Data Announcement Fails to Support Price - Stocks Telegraph
Pliant Therapeutics stock jumps on promising cancer drug trial results By Investing.com - Investing.com South Africa
Pliant Therapeutics stock jumps on promising cancer drug trial results - Investing.com
Pliant Therapeutics, Inc. Announces Interim Data from Pln-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - marketscreener.com
Pliant’s PLN-101095 shows promising results in cancer trial - Investing.com India
Pliant Therapeutics reveals promising early results for PLN-101095 - Traders Union
Pliant Therapeutics announces interim data from PLN-101095 - marketscreener.com
Pliant Therapeutics (Nasdaq: PLRX) reports interim PLN-101095 data with 1 CR, 3 PRs - Stock Titan
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Sahm
Is Pliant Therapeutics Inc. (9PT) stock considered safe havenTrade Volume Report & Community Consensus Stock Picks - Newser
Are Smart Investors Making the Right Decision? Pliant Therapeutics Inc (PLRX) - setenews.com
Will Pliant Therapeutics Inc. (9PT) stock profit from fiscal stimulusMarket Risk Summary & Verified Swing Trading Watchlist - Newser
Will Pliant Therapeutics Inc. stock attract more institutional investors - Newser
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - Investing News Network
Pliant Therapeutics Inc Stock Analysis and ForecastRSI Overbought/Oversold & Insights From Wall Street Professionals - earlytimes.in
What drives Pliant Therapeutics Inc stock priceCapital Gains Strategies & Access Advanced Stock Screening Tools - earlytimes.in
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.36%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):